

Villers-lès-Nancy, 20 November 2024 - 6:00 p.m. (CET)

PRESS RELEASE

Equasens Group and Posos join forces to transform pharmacy dispensing processes through innovative artificial intelligence

[Equasens Group](#) (Euronext Paris™ - Compartiment B - FR 0012882389 -EQS), a leading provider of digital healthcare solutions, and Posos, an AI medical technology specialist, announce a strategic partnership to automate and secure the key phases of pharmacy dispensing processes.

The addition of the "*id.genius*" module into the Pharmagest Divisions's *id.* software suite improves the quality and control of dispensing processes, and, in so doing, enhances the security of drug distribution channels and the patient care pathway.

Helping pharmacists meet today's challenges

Retail pharmacists are responsible for drug dispensing activities which include pharmaceutical analysis of prescriptions, eventually dose administration and advising the public on the proper use of medicines. In a context of staff shortages and the increasing complexity of prescriptions, pharmacists are required to exercise time-consuming and "high-risk" tasks on a daily basis. These include manually processing prescriptions, checking for drug interactions, and managing stock shortages. According to the Unions of Pharmacists, pharmacies spend up to 12 hours a week performing these tasks. However, by integrating Posos' AI capabilities into the Pharmagest Division's *id.* software suite with the "*id.genius module*", these steps can now be automated, saving valuable time and reducing the risk of error.

Secure, simplified drug delivery

This new technological partnership will add Posos' AI capabilities to the Pharmagest Division's *id.* software suite used by more than 8,400 pharmacies in France. These AI capabilities are based on a multilingual medical database certified by the French National Health Authority (HAS) and natural language processing (NLP) models developed specifically to understand medical language. By automatically converting prescriptions into structured data, pharmacies are able to receive personalised medical recommendations in real time directly through their *id.* software suite, resulting in a faster and safer dispensing process.

Concrete benefits to pharmacies of the *id.genius* model include:

- **Automated prescription entry:** paper and electronic prescriptions are automatically captured by AI, and the treatments to be delivered are transcribed.
- **Proposition of alternatives:** in the event of a disruption in supply or incompatibility of treatment, alternatives adapted to the patient's profile are suggested.

- **Real-time control:** automated verification between prescribed and dispensed drugs improving dispensing safety.
- **Dosage labels:** labels are automatically pre-printed to ensure safe treatment management.

More time to assist and monitor patients

This technology helps pharmacists focus on assisting and advising patients, by reducing administrative workloads. *"By adding Posos' innovative AI to our id. software suite, we are responding directly to the needs of dispensing pharmacists in meeting challenges like the increasing complexity of prescriptions and in-pharmacy time management, aggravated by the context of staff shortages and drug supply disruptions. This partnership highlights our commitment to offering technological solutions that not only secure and optimise the drug distribution process, but above all help pharmacists to refocus on their core mission of advising and supporting patients. What's more, it saves time and reduces the risk of errors through automated pharmacy dispensing systems, by eliminating the need for pharmacy staff to manually enter prescriptions at the counter"* declared Denis Supplisson, Chief Executive Officer of Equasens Group.

A complete range of solutions for securing drug distribution channels

The Equasens Group has thus strengthened its offering for securing the drug distribution channel. The *id.genius* module for securing the drug dispensing process enhances the Group's existing range of solutions that include pharmacy consultation aids, label printing (*id.Posologie*), therapeutic compliance with Multimeds (pill dispenser, robot and software for the preparation of pill dispensers) and patient applications.

This new service is fully in line with the Group's strategy of facilitating the day-to-day work of healthcare professionals and their teams, to provide better patient care and a more efficient healthcare system, in keeping with its motto *"More Technology for a More Human Experience"*.

Posos' AI technology, already used by hospitals, is now being deployed in pharmacies

After the successful completion of the pilot phase, this innovation will be offered as an option to the 8,400 pharmacies already equipped with the *id.* software suite as part of a gradual roll-out. *"Posos has designed its AI technology to analyse prescriptions using a personalised and secure approach in all healthcare settings, both for office-based practice and hospitals, while adapting to the specific characteristics of each country. We are delighted by this opportunity to take this next step in making it available to dispensing pharmacists in partnership with a major player in the digital healthcare sector like Equasens Group,"* added Emmanuel Bilbault, Posos' CEO and co-founder.

About Equasens Group

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.



Listed on Euronext Paris™ - Compartment B

Indices: MSCI GLOBAL SMALL CAP - GAIA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label



Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on [LinkedIn](#)

CONTACTS

Equasens Group

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel.: +33 (0)3 83 15 90 67 – frederique.schmidt@equasens.com

Noëlle Stoulig, Equasens Group Communications Director

communication@equasens.com

Financial communications agency:

FIN'EXTENSO - Isabelle Aprile

Tel.: +33 (0)3 17 38 61 78 – i.aprile@finextenso.fr

About POSOS

Posos is a French medtech developing solutions for clinical and dispensing pharmacies to increase the security of drug distribution processes, strengthen collaboration with prescribers and leverage pharmaceutical expertise to combat the phenomenon of iatrogenesis. Through its unique, proprietary artificial intelligence models applied to medical language and its comprehensive drug database approved by the French National Health Authority (HAS), Posos streamlines and optimizes key pharmacy processes: shared drug evaluations, analysis of complex prescriptions and personalized therapeutic alternatives. Founded in 2018 by a team of pharmacists and engineers, Posos helps pharmacists focus on providing clinical support to patients throughout their care pathway.

Find out more at www.posos.co

Press contact:

Zoé Vilan

zoe.vilan@posos.fr